Regeneron Pharmaceuticals, Inc. (REGN) Income Statement

The revenue trajectory shows a clear deceleration from the double-digit growth seen in mid-2024 to low-single-digit or even negative growth in recent quarters. The 16.7% growth in 2026Q2 is an outlier, likely driven by a one-time event or timing of shipments, as the preceding quarters grew only 0.9% to 3.6%. This pattern suggests that the core products, particularly Eylea, are facing increased competition and market saturation. Investors should monitor whether the company can sustain any growth above the low-single-digit range, as the pipeline may not yet offset the erosion in the base business.

The gross margin contraction is a notable trend, moving from a stable 85-87% range in 2024 to 81-82% in 2026. This decline suggests that the company is either absorbing higher production costs or facing pricing pressure on its key products. The 2026Q2 gross margin of 81.2% is the lowest in the ten-quarter period, which could signal a structural shift rather than a temporary blip. If this trend continues, it will compress operating leverage and reduce the company's ability to fund R&D at current levels. The company's gross margin remains above peers like Biogen (70.5%) but below Incyte (92.8%), indicating a competitive but not best-in-class position.

The operating leverage that was evident in 2024, when operating margins expanded to over 30%, has reversed. In 2026Q1, operating income was only $642.9 million on revenue of $3.6 billion, a margin of 17.8%, despite revenue growing 19% year-over-year. This suggests that R&D and SG&A expenses are growing faster than revenue, possibly due to increased investment in pipeline development and commercialization efforts. The 2026Q2 recovery to 30.1% is encouraging but may be volatile. The company's operating margin is now below Vertex's 39.4%, indicating that it is not generating the same level of efficiency from its revenue base.

The cost structure is dominated by R&D, which has consistently been the largest expense line, exceeding SG&A in every quarter. R&D spending has grown by about 33% over the period, from $1.2 billion to $1.6 billion, while revenue grew only about 39% over the same period, indicating that R&D intensity is stable. This level of investment is typical for a biotech company but leaves little room for cost reduction without sacrificing future growth. SG&A has also increased, particularly in 2025Q4 and 2024Q4, which may reflect higher commercialization costs. The company's ability to manage these costs while maintaining revenue will be key to margin expansion.

The 2025Q1 revenue decline was the first negative growth quarter in the provided data, and it was followed by only modest recoveries. This inflection likely reflects the impact of biosimilar competition to Eylea and possibly a slowdown in demand. The subsequent quarters have not returned to the double-digit growth rates seen in 2024, indicating that the company's growth engine has shifted. The lasting impact is a lower growth trajectory, which may persist until new products contribute meaningfully. This period also saw a dip in operating margin to 19.5%, highlighting the cost pressures that accompanied the revenue slowdown.